The obesity and metabolic drug space is suddenly in the spotlight, and not just because of headlines around GLP-1 treatments. A Supreme Court ruling on executive power, Medicare’s move to start covering obesity drugs, and a record close for the Dow are all feeding into a new conversation about where risk and opportunity may sit in this corner of healthcare. This article looks at 3 stocks from our Healthcare Sector, Obesity and Metabolic Drug Manufacturers screener that appear particularly exposed to these developments, helping you evaluate which stories might warrant closer attention now.

Madrigal Pharmaceuticals (MDGL)

Overview: Madrigal Pharmaceuticals focuses on treatments for metabolic dysfunction associated steatohepatitis (MASH), anchored by its approved drug Rezdiffra, a liver targeted thyroid hormone receptor beta agonist for patients in the United States.

Operations: Madrigal generates about US$1.1b from delivering novel MASH therapeutics, with all reported revenue currently coming from the United States.

Market Cap: US$12.2b

Madrigal Pharmaceuticals sits at the crossroads of rising interest in obesity related therapies and the emerging MASH treatment market, with Medicare’s openness to metabolic drugs adding fresh attention to its story. Rezdiffra is protected by long dated patents and supported by growing clinical and real world evidence. The company still depends heavily on this single asset, faces GLP 1 competition and remains loss making, with a recent quarterly net loss of US$94.39 million. Investors may also wish to weigh factors such as reimbursement pressure, financing needs and governance signals such as high executive pay and ongoing board refresh.

Madrigal Pharmaceuticals is already tied to a high profile MASH launch, but the real story could be how its single drug reliance shapes risk and reward. Step through the analysis report for Madrigal Pharmaceuticals to see what that concentration might really mean for the next chapter.

Rhythm Pharmaceuticals (RYTM)

Overview: Rhythm Pharmaceuticals is a commercial stage biopharma company that develops IMCIVREE and other therapies for rare, genetically driven forms of obesity and neuroendocrine disease. The company aims to treat patients whose weight issues stem from specific defects in the melanocortin-4 receptor pathway rather than lifestyle alone.

Operations: Rhythm generates about US$217.2m from therapies for patients with rare diseases, with roughly US$146.1m from the United States and US$71.1m from international markets.

Market Cap: US$7.5b

Rhythm Pharmaceuticals offers focused exposure to obesity and metabolic drugs without competing directly in the crowded GLP 1 field. This positioning may be relevant as Medicare starts covering obesity treatments and investor interest broadens beyond mainstream brands. IMCIVREE sits at the center of multiple rare disease programs, with recent data in acquired hypothalamic obesity and Prader Willi syndrome supporting a widening addressable patient pool. At the same time, the company still relies heavily on this franchise while reporting ongoing losses and funding its pipeline through higher risk borrowing. With analysts assigning ambitious upside, a premium P/S and frequent positive trial readouts, the balance between long term opportunity and execution, pricing and reimbursement risk is a key consideration for this screener.

Rhythm Pharmaceuticals sits at the intersection of rare disease focus and rising interest in obesity drugs, yet IMCIVREE reliance and debt funded development leave key questions open. Weave together the growth story and hidden pressure points through the analyst forecasts for Rhythm Pharmaceuticals to see what could be missing.

Protagonist Therapeutics (PTGX)

Overview: Protagonist Therapeutics is a US based biotech company developing peptide based drugs for immune mediated skin diseases, rare blood disorders and obesity, including oral and injectable candidates that target pathways like IL 17, hepcidin and amylin receptors.

Operations: Protagonist Therapeutics generates about US$74.1m in revenue from biotechnology activities, all reported from the United States.

Market Cap: US$7.8b

Protagonist Therapeutics provides exposure to a broad peptide drug pipeline that links autoimmune skin disease, rare blood disorders and obesity. Medicare coverage is set to widen interest in metabolic treatments. Forecasts for earnings and revenue growth, alongside expectations of profitability within 3 years and a share price cited as sitting below one DCF based fair value estimate, present a particular risk reward profile, but the company remains unprofitable today, carries funding risk from external borrowings and has seen meaningful insider selling and high executive pay. With fresh Phase 3 rusfertide data, new hires and improving recent earnings, investors may consider whether current optimism fully reflects the potential upside or still underestimates what the obesity and metabolic programs could contribute.

Protagonist Therapeutics appears to be an accelerating story in which obesity and rare disease programs could be masking a very different risk reward profile. Walk through the 2 key rewards and 1 important warning sign to see what the recent optimism might be missing.

The three stocks highlighted here are just a starting point, and the full Healthcare Sector - Obesity and Metabolic Drug Manufacturers screener surfaces 19 more companies whose obesity and metabolic drug stories may be just as compelling. Use Simply Wall St to identify, analyze and filter for the specific catalysts, risk flags and narratives that matter to you so you can focus on the highest conviction ideas in this space.

Take Control of Your Investment Journey

If Protagonist Therapeutics or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Obesity?

Markets move fast and the next breakout themes rarely stay under the radar for long. Scan these fresh stock ideas before the crowd catches up and act now.

• Spot income workhorses with staying power by reviewing 9 dividend fortresses, built to highlight companies combining hefty yields with balance sheets that can handle real world stress.
• Ride the momentum in critical metals by checking the curated 8 top copper producer stocks that zeroes in on producers positioned at the heart of electrification and infrastructure demand.
• Get ahead of the next automation wave with the focused 29 robotics and automation stocks showcasing businesses building robots, sensors and software that could reshape how core industries operate.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.